top:ctdna as a recurrence biomarker after resection

Q: top:ctdna as a recurrence biomarker after resection

Summary The provided research passages do not contain evidence regarding ctDNA as a recurrence biomarker after resection. The available guidelines focus on imaging-based staging [2], response criteria for tumor size and metabolic activity (pRECIST) [5], and management algorithms for borderline-resectable or locally advanced disease [3]. Consequently, this service cannot answer the specific question based on the provided high-tier sources. Evidence The NCCN Clinical Practice Guidelines focus on diagnosis, systemic therapy, radiation, and surgical resection but do not mention ctDNA monitoring [1]. ACR Appropriateness Criteria identify multiphase contrast-enhanced multidetector CT and MRI as the modalities of choice for pretreatment staging and presurgical determination of resectability, with EUS and PET/CT indicated for specific scenarios like biopsy guidance or confirming distant metastases [2]. The REDISCOVER guidelines provide a management algorithm for borderline-resectable and locally advanced pancreatic cancer, prioritizing tumor biology over anatomical features, but do not address post-resection recurrence monitoring via ctDNA [3]. pRECIST guidelines establish standardized criteria for measuring pancreatic tumor metabolic activity and size changes in trials, particularly in the neoadjuvant setting, using CT/PET assessments rather than liquid biopsy markers [5]. Caveats The evidence is limited to clinical guidelines that do not address the specific biomarker of interest. There is an absence of data from randomized trials or systematic reviews regarding ctDNA utility in this context within the provided text. The available literature focuses on anatomical imaging and metabolic response criteria rather than molecular recurrence monitoring.

Question

Accepted Answer

Summary

The provided research passages do not contain evidence regarding ctDNA as a recurrence biomarker after resection. The available guidelines focus on imaging-based staging [2], response criteria for tumor size and metabolic activity (pRECIST) [5], and management algorithms for borderline-resectable or locally advanced disease [3]. Consequently, this service cannot answer the specific question based on the provided high-tier sources.

Evidence

The NCCN Clinical Practice Guidelines focus on diagnosis, systemic therapy, radiation, and surgical resection but do not mention ctDNA monitoring [1].

ACR Appropriateness Criteria identify multiphase contrast-enhanced multidetector CT and MRI as the modalities of choice for pretreatment staging and presurgical determination of resectability, with EUS and PET/CT indicated for specific scenarios like biopsy guidance or confirming distant metastases [2].

The REDISCOVER guidelines provide a management algorithm for borderline-resectable and locally advanced pancreatic cancer, prioritizing tumor biology over anatomical features, but do not address post-resection recurrence monitoring via ctDNA [3].

pRECIST guidelines establish standardized criteria for measuring pancreatic tumor metabolic activity and size changes in trials, particularly in the neoadjuvant setting, using CT/PET assessments rather than liquid biopsy markers [5].

Caveats

The evidence is limited to clinical guidelines that do not address the specific biomarker of interest. There is an absence of data from randomized trials or systematic reviews regarding ctDNA utility in this context within the provided text. The available literature focuses on anatomical imaging and metabolic response criteria rather than molecular recurrence monitoring.